Engflag

BelAIR

Quick links to important sections

BelAIR

BelAIR_EN

Method of action: Anti-Bronchoconstrictive, Anti-Inflammatory, Bronchodilator, Drugs For Obstructive Airway Diseases

Treatment option: Asthma, Exercise-Induced Bronchoconstriction, Rhinitis, Hay Fever

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of BelAIR

Property Description
Active ingredient Montelukast (as Montelukast Sodium)
Form Tablets, Chewable Tablets, Oral Granules
Pharmacological class Leukotriene Receptor Antagonist (CysLTRA)
Origin Synthetic small molecule compound
Route Oral administration

What Type of Medicine is BelAIR (Montelukast)?

BelAIR is a pharmaceutical preparation containing the active ingredient Montelukast, a prescription-only molecule clinically recognized as a highly selective Leukotriene Receptor Antagonist (LRA). This type of drug is primarily utilized as maintenance therapy to manage chronic inflammation, distinguishing it from medications used for immediate, acute relief. Montelukast is a single-ingredient product whose mechanism—blocking the action of specific inflammatory mediators—has been supported by pharmacological studies since its introduction.

The specific classification is a Cysteinyl Leukotriene Receptor Antagonist (CysLTRA), which confirms its targeted, synthetic approach. Unlike broad anti-inflammatory treatments such as inhaled corticosteroids, this medicine provides a distinct, non-corticosteroid mechanism that directly intercepts the leukotriene signaling pathway.

Composition, Origin, and Available Forms

The composition of BelAIR is based on Montelukast Sodium as the active substance, a quinoline derivative confirming its entirely synthetic origin. The active component is formulated alongside excipients into various solid oral dosage forms. A key feature of the compound is the range of convenient presentations available for oral administration, including conventional film-coated tablets, chewable tablets, and oral granules. This flexibility in form supports effective treatment adherence across different patient age groups.

The General Purpose of a Leukotriene Receptor Antagonist

The overall general purpose of a CysLTRA like Montelukast is to establish a molecular blockade that preemptively suppresses specific inflammatory responses. By binding to the CysLT1 receptor, the medication prevents potent leukotrienes from causing swelling and the construction of smooth muscles in the airways. This action sustains wider bronchial passages and reduces the underlying inflammatory burden, serving as an essential component of long-term management for conditions where chronic inflammation is a key feature.

Regulatory References

  1. Montelukast - StatPearls - NCBI Bookshelf

What side effects are possible with BelAIR?

The official safety profile for BelAIR (Montelukast) outlines adverse reactions based on their documented frequency in regulatory documents, classifying them by System-Organ-Class (SOC).

Adverse Reactions and Frequencies

Adverse reactions classified as Very Common (ge 1/10) include Upper respiratory infection. Common events (ge 1/100 to <1/10) typically involve the gastrointestinal system, such as abdominal pain, nausea, and diarrhoea, alongside general events like headache and fever. Less common events fall into the Uncommon and Rare categories, affecting systems like the skin (e.g., rash), or resulting in sleep disturbances.

Serious Adverse Reactions

The regulatory labels highlight specific, rare, but clinically important adverse reactions. These include a risk of neuropsychiatric events such as suicidal thoughts and behaviour (Very Rare), which are documented in post-marketing reports and emphasized in prominent regulatory warnings. Additionally, cases of systemic eosinophilia with vasculitis, consistent with Churg-Strauss Syndrome (Very Rare), have been reported, often associated with reducing or withdrawing oral corticosteroids. Immediate, severe reactions like Anaphylaxis are listed as Uncommon.

Population and Formulation Safety Constraints

The medicine is strictly contraindicated in individuals with known hypersensitivity to the active substance. Specific formulation constraints exist: the chewable tablet contains aspartame, a source of phenylalanine, which is a constraint for individuals with Phenylketonuria (PKU). No dosage adjustment is required for patients with mild-to-moderate hepatic impairment. The safety profile has been documented to remain stable with extended, long-term treatment.

The official safety information structures the understanding of risks by categorizing adverse reactions based on their documented frequency and physiological impact. The SOC classification and specific warnings about neuropsychiatric changes and systemic hypersensitivity define key areas for safety monitoring, while population constraints clarify regulatory limitations on the drug’s use in certain individuals.

Overdose and Emergency Response

The official regulatory documentation for BelAIR (Montelukast) overdose describes specific clinical signs observed following acute exposure. Manifestations reported across both adult and pediatric cases primarily involve the gastrointestinal and central nervous systems. Documented symptoms include abdominal pain, vomiting, and thirst. CNS effects may present as somnolence or headache, with some reports noting psychomotor hyperactivity or agitation.

In the event of suspected overdose, government regulatory authorities mandate that medical attention or advice be sought immediately, typically by contacting a regional Poison Control Center or emergency services. This action is required despite reports indicating that the majority of acute overdose events have occurred without resulting in clinically important adverse experiences.

The treatment protocol, as defined in the official prescribing information, is entirely symptomatic and supportive. No specific pharmacological antidote is known for Montelukast overdose. Furthermore, it is not known whether the substance can be removed from the body through dialysis procedures such as hemodialysis. Clinical monitoring is essential to manage any presenting symptoms. Overdose cases have been reported in children as young as 3.5 years old and in adults with doses up to 1000 mg.

Therapeutic Uses of BelAIR

BelAIR: Main Uses and Therapeutic Focus

BelAIR is a prescribed medication used in the management of certain allergic and inflammatory conditions. Its primary therapeutic applications focus on controlling symptoms and reducing the frequency of severe events in specific patient populations.

Clinical Applications and Benefits

BelAIR is indicated as an add-on therapy for improving asthma control in patients who have moderate-to-severe persistent allergic asthma that is not adequately managed with inhaled corticosteroids. For this use, patients must have a positive test to an allergen in the air, such as dust mites or pollen. The medication works to reduce the incidence of asthma exacerbations and daily symptoms.

BelAIR is also utilized as add-on therapy to reduce the signs and symptoms of chronic spontaneous urticaria (CSU) in adults and adolescents who have an inadequate response to H1 antihistamine treatment. Additionally, it is used for chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients who have not achieved adequate disease control with intranasal corticosteroids. The use of BelAIR may also be considered to reduce the risk of allergic reactions, including anaphylaxis, following accidental exposure to multiple foods in certain individuals with food allergies.

Quick Facts: What BelAIR Treats
Asthma Control: Moderate-to-severe persistent allergic asthma
Chronic Urticaria: Chronic spontaneous urticaria (CSU) in patients with inadequate response to antihistamines
Nasal Inflammation: Chronic rhinosinusitis with nasal polyps (CRSwNP)
Allergic Reactions: Reduction of allergic reactions, including anaphylaxis, from accidental multiple food allergen exposure

Regulatory References

  1. EMA therapeutic overview

Eligibility and Restrictions for Use

Who can and cannot use BelAIR?

The population eligibility rules for BelAIR (Montelukast) are defined by official government regulatory authorities and establish the conditions for use and exclusion.

Contraindicated Populations (Must Not Use)
Patients with a known hypersensitivity to Montelukast or any component of the formulation.
Use for the treatment of an acute asthma attack or status asthmaticus.
Age-Related Eligibility Restriction/Status
Asthma: Patients ge 12 months of age. Use not established below this age.
EIB Prevention: Patients ge 6 years of age. Use not established below this age.
Older Adults: ge 65 years. No dosage adjustment required.

Eligibility is further restricted for certain conditions:

  • Hepatic Impairment: Use is not recommended in patients with severe hepatic impairment due to a lack of clinical data. Mild-to-moderate impairment requires no adjustment.
  • Formulation Restrictions: The chewable tablets are restricted for patients with Phenylketonuria (PKU). Tablets are restricted for patients with galactose intolerance (due to lactose content).
  • Pregnancy and Lactation: Use is generally conditional and recommended only if clearly essential.

What should I know about interactions with other medicines?

Interactions with other medicines and products

BelAIR (Montelukast) interaction patterns are primarily defined by documented changes in systemic exposure caused by metabolic enzyme activity and by a key pharmacodynamic restriction.

Pharmacokinetic and Metabolic Interactions

Montelukast is metabolized by Cytochrome P450 (CYP) enzymes, specifically CYP 2C8, 2C9, and 3A4. Co-administration with potent CYP enzyme inducers such as Phenobarbital or Rifampicin results in a reduction of Montelukast systemic exposure (AUC) by approximately 40%, a circumstance for which caution is noted in regulatory documents. Conversely, the CYP enzyme inhibitor Gemfibrozil is documented to increase Montelukast systemic exposure by 4.4-fold. However, routine dosage adjustment is not required.

Co-administration with Theophylline, Warfarin, Digoxin, or common oral contraceptives does not result in clinically important pharmacokinetic effects according to official prescribing information.

Pharmacodynamic and Substance Restrictions

Official labeling contains a mandatory restriction for patients with known aspirin-sensitive asthma: Montelukast treatment does not alter the requirement to continue to avoid aspirin and other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). The bronchodilation effect of a beta-agonist is noted as being additive to the effect of Montelukast.

Administration Context

Montelukast may be administered without regard to the timing of food ingestion. Caution regarding reduced systemic exposure is advised when co-administering with CYP enzyme inducers in the pediatric patient population.

Mechanism of Action

How BelAIR Works: Mechanism of Action

BelAIR is a selective antagonist that exerts its action by binding to the CysLT1 (Cysteinyl Leukotriene Type 1) receptors located on the surface of various cells, including smooth muscle and immune cells in the airways. This interaction blocks the binding site, preventing the body's endogenous inflammatory mediators, the cysteinyl leukotrienes (CysLTs), from activating the receptor. By interrupting this signaling, BelAIR modulates the leukotriene pathway activity.

This specific receptor blockade limits the typical downstream cascade of CysLT-mediated effects, which include increased smooth muscle contraction and enhanced vascular permeability in the airway lining. The resultant physiological modulation is characterized by decreased muscle tone in the bronchi and a reduction in vascular leakage and associated tissue swelling. This focused alteration of the CysLT signaling pathway influences the dynamics of the pulmonary smooth muscle system.

Dosage and Administration Information

BelAIR is administered exclusively by the oral route and is available in three dosage forms: a film-coated tablet, a chewable tablet (5 mg and 4 mg), and 4 mg oral granules. The medication is intended for chronic treatment and must be taken continuously on a once-daily schedule for prophylaxis, even during periods of sustained asthma control.

Dosing and Administration Schedule

The dosing regimen is standardized based on age. Adults and adolescents 15 years and older are administered a 10 mg tablet once daily. For pediatric patients, the dose is 5 mg for ages 6 to 14, and 4 mg for ages 2 to 5. These doses represent the maximum recommended daily amount for their respective age groups. For individuals managing asthma, the dose is typically consumed in the evening.

The medicine may be taken with or without food. Special administration rules apply to the oral granules: the contents must be mixed with a spoonful of soft foods (such as applesauce, carrots, rice, or ice cream) or a small volume (5 mL) of cold breast milk or baby formula, and the full dose must be ingested within 15 minutes of opening the packet. The granules should not be mixed with other liquids.

In scenarios requiring prophylaxis against Exercise-Induced Bronchoconstriction (EIB), a single dose must be taken at least two hours prior to exercise. It is mandatory that an additional dose not be taken within 24 hours of this pre-exercise dose. No dosage adjustment is required for older adults or for individuals with mild to moderate renal or hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for BelAIR (Montelukast)

Evidence for Use in Asthma Control and Exercise-Induced Bronchoconstriction

Research examining BelAIR for persistent asthma primarily relies on Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies were studied for adults, adolescents, and children, often as an add-on to inhaled corticosteroids (ICS). Research monitored objective outcomes, such as changes in lung capacity measurements (FEV1), and tracked the frequency of acute or disruptive episodes (asthma exacerbations). Findings describe patterns observed in the studies where differences in lung function measurements were documented between study groups compared to placebo.

The use of BelAIR for was studied for exercise-induced bronchoconstriction (EIB) was evaluated in acute challenge studies. Findings indicate patterns related to differences in lung function measurements when the medicine was observed in trials taken shortly before the exercise test.

Evidence for Use in Allergic Rhinitis, CSU, and Nasal Polyps

Numerous RCTs explored the use of BelAIR for both seasonal and perennial allergic rhinitis, monitoring changes in nasal symptom scores and sleep quality. Evidence suggests the magnitude of the reported difference may be lower compared to other standard rhinitis therapies that were studied for rhinitis.

For less common uses, such as Chronic Spontaneous Urticaria (CSU) and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), research primarily involves short-term, add-on studies. For both indications, findings were mixed, with differences in reported symptom scores observed in some studies when the medicine was studied for its use with standard treatments.

Long-Term Studies and What is Still Uncertain

Key research trials monitored patients over short-term to intermediate-term intervals (up to a year). Long-term effects are not fully established beyond these periods. Evidence quality varies across studies, and subgroup findings are uncertain, as observed patterns of change were often restricted to specific patient groups, such as children or those with coexisting asthma. Inter-individual variability in response was observed in some studies, meaning that the pattern of change may differ significantly from person to person.

Frequently Asked Questions (FAQ)

Common questions about BelAIR (FAQ)

Q: How quickly can a person expect BelAIR to start working?

A: Official clinical information indicates that the medicine causes bronchodilation—a widening of the airways—within two hours of taking a dose. However, the medicine is intended for chronic, long-term management of your condition. As a maintenance therapy, it is not approved for use in immediate, acute relief situations.

Q: Can BelAIR be taken by people who have mild kidney issues?

A: Official prescribing information states that no dosage adjustment is generally required for individuals who have mild to moderate renal impairment (kidney issues). However, official labeling does not contain specific studies for severe kidney problems. The determination of suitability is made by a healthcare provider.

Q: Can elderly patients use BelAIR safely?

A: Studies and official information indicate that the way the body processes the medicine is similar in elderly patients (age 65 and older) compared to younger adults, and no dosage adjustment is required. The safety profile has been documented in regulatory sources to remain consistent over intermediate-term studies in this population.

Q: What if I experience unusual mood changes while on BelAIR?

A: Regulatory warnings specifically highlight the risk of neuropsychiatric events, which include changes in mood, behavior, and thoughts of self-harm. Official labeling advises that patients should contact a healthcare provider immediately if changes in behavior or new symptoms are experienced, and the medicine should be discontinued.

Q: Is there a specific time of day BelAIR is typically recommended for use?

A: Yes, the recommended timing depends on the condition being addressed. For managing asthma or perennial allergic rhinitis, the dose is typically recommended once daily in the evening. If it is being taken specifically for the prevention of exercise-induced bronchoconstriction (EIB), the dose must be taken at least two hours prior to exercise.

Q: Can I crush or split the BelAIR tablet/capsule?

A: The official instructions for using the medicine are very specific, especially for the oral granule form. Regulatory documents do not contain instructions or authorization for crushing or splitting the film-coated or chewable tablets, which may compromise the designed delivery of the medicine.

Q: Can BelAIR be used by individuals with diabetes?

A: Official regulatory documents do not list diabetes as a contraindication or warning that would prohibit use. The product information does not indicate a known clinically significant interaction with common diabetes treatments. The determination of suitability for any individual, including those with diabetes, is made by a healthcare provider.

Q: Does BelAIR affect birth control pills?

A: Studies examining the co-administration of this medicine with a common oral contraceptive indicated that the medicine did not cause clinically important effects on the pharmacokinetics of the oral contraceptive components. This means it is generally not expected to interfere with the way the birth control pill is processed by the body.

Q: Is BelAIR used for conditions other than the primary one mentioned?

A: Yes, the medicine is FDA-approved and commonly used for more than one condition. In addition to being used for chronic asthma and prevention of exercise-induced breathing difficulty, it is also approved to relieve symptoms of both seasonal and perennial allergic rhinitis (hay fever or year-round allergies).

Q: What happens if BelAIR is accidentally stopped suddenly?

A: The medicine is not a steroid and does not typically require a gradual dose reduction (tapering). The medicine is described in official documentation as being intended for continuous, chronic use. Regulatory data indicates that neuropsychiatric symptoms that led to stopping the drug resolved in many patients, but in some cases, symptoms persisted even after stopping the medicine.

Q: How long does BelAIR stay in the body after the last dose?

A: Pharmacokinetic data from regulatory documents indicate that the average plasma half-life of the active ingredient (montelukast) ranges from approximately 2.7 to 5.5 hours in healthy young adults. The half-life is the time it takes for half of the drug to be eliminated from the bloodstream.

Q: Is BelAIR known to interact with herbal supplements?

A: Official regulatory documents focus on detailing interactions with common prescription medications that are known to significantly affect the body's CYP 450 enzyme system. The labeling does not specifically list or warn against interactions with common over-the-counter or herbal supplements.

Q: Is there a risk of allergic reactions to BelAIR?

A: Yes, official labeling lists a known hypersensitivity to any component of the formulation as a condition where the medicine must not be used (a contraindication). Post-marketing reports also documented rare, severe allergic reactions like anaphylaxis and angioedema (swelling beneath the skin).

Q: How to Store and Dispose of BelAIR?

A: Official product information requires that the medicine be stored at Controlled Room Temperature (between 20 C and 25 C). The tablets or granules should be kept in their original container to protect them from moisture and light. Official instructions specify that any outdated or unneeded medicine should be disposed of according to the guidelines set by local waste disposal authorities.

Q: Is BelAIR known to be habit-forming?

A: No, official regulatory authorities do not classify the active ingredient (montelukast) as a controlled substance or scheduled drug. This classification indicates that the medicine is not considered to be habit-forming.

Q: Is BelAIR suitable for children or adolescents?

A: Yes, the safety and effectiveness of the medicine are established for asthma in children as young as 12 months of age. Different formulations and doses are approved for various pediatric age groups. For example, chewable tablets are approved for patients aged 2 years and older.

Q: Does the effectiveness of BelAIR decrease over time?

A: Regulatory data from clinical studies indicate that during continuous once-daily dosing, there is only little accumulation of the drug in the body. Clinical trials monitoring patients for up to a year generally showed sustained effectiveness within those study periods, with no noted loss of effect.

Q: Does BelAIR affect blood pressure readings?

A: Cardiovascular effects, such as changes in blood pressure, are not listed among the common, less common, or serious adverse reactions documented in regulatory documents. This indicates that it is not a typically reported side effect.

How should BelAIR be stored and disposed of?

How to Store and Dispose of BelAIR?

Official regulatory information requires BelAIR (budesonide inhalation suspension) to be stored under specific conditions to maintain stability and potency.

Storage Component Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C). Do not freeze or refrigerate.
Light Protection Keep the unit dose ampoules in the original foil pouch/outer carton to protect from light.
Stability After Opening The contents of an opened single-dose ampoule must be used immediately; discard any unused solution. Ampoules in an opened foil pouch have a limited in-use stability period (check specific label).
Disposal Discard any unused solution immediately after use. Dispose of outdated or unneeded medicine according to local requirements.
General Handling Store ampoules in an upright position and keep the product out of the reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagSouth Africa

Equivalent of BelAIR found in:

A-Z Index: